Search clinical trials for: BIBR 796 BS, 20 mg

Total 942 results

Boehringer Ingelheim

Terminated

Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease

Crohn Disease
Boehringer Ingelheim

Completed

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Terminated

Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Excretion Balance of 14c-radiolabeled BIRB 796 BS in Normal Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of Oral BIRB 796 BS Tablets With and Without Administration of Oral Pantoprazole in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment

Healthy
Boehringer Ingelheim

Withdrawn

Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

Pulmonary Disease, Chronic Obstructive | Bronchitis, Chronic

United States, France, Germany
Boehringer Ingelheim

Completed

Effect of BIBW 2948 BS in COPD

Pulmonary Disease, Chronic Obstructive | Bronchitis, Chronic

United States, Germany
Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache

Migraine Disorders
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS for HandiHaler® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects

Healthy
Boehringer Ingelheim

Terminated

Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

HIV Infections

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIBN 4096 BS in Healthy Male and Female Volunteers

Healthy
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
Vanda Pharmaceuticals

Completed

Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)

Non-24-Hour-Sleep-Wake Disorder
Boehringer Ingelheim

Completed

Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers

Healthy
Eisai Co., Ltd.

Completed

A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects

Healthy Subjects

Japan
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects

Pharmacokinetics

Germany
Peking Union Medical College Hospital

Not yet recruiting

Avatrombopag Usage in NSAA

Drug Effect | Aplastic Anemia

China
Pfizer

Completed

A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

Alopecia Areata

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Healthy

United States
Chong Kun Dang Pharmaceutical

Completed

Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects

Dyslipidemias

Korea, Republic of
Oncology Institute of Southern Switzerland

Withdrawn

Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells

Prostate Cancer

Switzerland
Tourmaline Bio, Inc.

Recruiting

A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease (spiriTED)

Thyroid Eye Disease

United States, Jordan
Xenon Pharmaceuticals Inc.

Completed

A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder (X-NOVA)

Major Depressive Disorder

United States
Pfizer

Completed

STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT

Healthy | Diabetes Mellitus, Type 2 | Renal Impairment

United States
Instituto Nacional de Cancerologia de Mexico
Roche Pharma AG

Active, not recruiting

Tocilizumab Treatment in Patients With COVID-19

Sars-CoV2

Mexico
University of Utah

Completed

Remimazolam Sedation for Nerve Blocks (REMI-SEN)

Procedural Pain | Procedural Anxiety

United States
AstraZeneca

Completed

BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects

Gastric Ulcer | Duodenal Ulcer | Reflux Esophagitis | Anastomotic Ulcer | Etc.

Japan
Daiichi Sankyo, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

Atopic Dermatitis

United States
University of Bologna
Ipsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaborators

Unknown

Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)

Non Small Cell Lung Cancer

Italy

3

Subscribe